Literature DB >> 24599127

Identification of FoxR2 as an oncogene in medulloblastoma.

Hideto Koso1, Asano Tsuhako, Eli Lyons, Jerrold M Ward, Alistair G Rust, David J Adams, Nancy A Jenkins, Neal G Copeland, Sumiko Watanabe.   

Abstract

Medulloblastoma is the most common pediatric brain tumor, and in ∼25% of cases, it is driven by aberrant activation of the Sonic Hedgehog (SHH) pathway in granule neuron precursor (GNP) cells. In this study, we identified novel medulloblastoma driver genes through a transposon mutagenesis screen in the developing brain of wild-type and Trp53 mutant mice. Twenty-six candidates were identified along with established driver genes such as Gli1 and Crebbp. The transcription factor FoxR2, the most frequent gene identified in the screen, is overexpressed in a small subset of human medulloblastoma of the SHH subtype. Tgif2 and Alx4, 2 new putative oncogenes identified in the screen, are strongly expressed in the SHH subtype of human medulloblastoma. Mutations in these two genes were mutually exclusive with mutations in Gli1 and tended to cooccur, consistent with involvement in the SHH pathway. Notably, Foxr2, Tgif2, and Alx4 activated Gli-binding sites in cooperation with Gli1, strengthening evidence that they function in SHH signaling. In support of an oncogenic function, Foxr2 overexpression transformed NIH3T3 cells and promoted proliferation of GNPs, the latter of which was also observed for Tgif2 and Alx4. These findings offer forward genetic and functional evidence associating Foxr2, Tgif2, and Alx4 with SHH subtype medulloblastoma. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599127     DOI: 10.1158/0008-5472.CAN-13-1523

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

2.  Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.

Authors:  Anthony P Y Liu; Brian Gudenas; Tong Lin; Brent A Orr; Paul Klimo; Rahul Kumar; Eric Bouffet; Sridharan Gururangan; John R Crawford; Stewart J Kellie; Murali Chintagumpala; Michael J Fisher; Daniel C Bowers; Tim Hassall; Daniel J Indelicato; Arzu Onar-Thomas; David W Ellison; Frederick A Boop; Thomas E Merchant; Giles W Robinson; Paul A Northcott; Amar Gajjar
Journal:  Acta Neuropathol       Date:  2019-12-04       Impact factor: 17.088

Review 3.  Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery.

Authors:  Branden S Moriarity; David A Largaespada
Journal:  Curr Opin Genet Dev       Date:  2015-06-04       Impact factor: 5.578

4.  Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma.

Authors:  Takahiro Kodama; Michiko Kodama; Nancy A Jenkins; Neal G Copeland; Huanhuan Joyce Chen; Zhubo Wei
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

5.  MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer.

Authors:  You-Jin Lu; Rong-Yu Liu; Kun Hu; Ying Wang
Journal:  Tumour Biol       Date:  2016-07-22

6.  FOXR2 Interacts with MYC to Promote Its Transcriptional Activities and Tumorigenesis.

Authors:  Xu Li; Wenqi Wang; Yuanxin Xi; Min Gao; MyKim Tran; Kathryn E Aziz; Jun Qin; Wei Li; Junjie Chen
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

7.  High expression of FOXR2 in breast cancer correlates with poor prognosis.

Authors:  Haiping Song; Wenshan He; Xiaoqing Huang; Huiqiong Zhang; Tao Huang
Journal:  Tumour Biol       Date:  2015-11-23

8.  FOXR2 contributes to cell proliferation and malignancy in human hepatocellular carcinoma.

Authors:  Xiao Wang; Bin He; Yong Gao; Yandong Li
Journal:  Tumour Biol       Date:  2016-02-05

9.  HOXB13 and ALX4 induce SLUG expression for the promotion of EMT and cell invasion in ovarian cancer cells.

Authors:  Hong Yuan; Hiroaki Kajiyama; Satoko Ito; Dan Chen; Kiyosumi Shibata; Michinari Hamaguchi; Fumitaka Kikkawa; Takeshi Senga
Journal:  Oncotarget       Date:  2015-05-30

10.  Differential expression of aristaless-like homeobox 4: a potential marker for gastric adenocarcinoma.

Authors:  Fariba Ghasemvand; Navid Nezafat; Saeed Hesami Tackallou; Daruosh Momenzadeh; Saeid Rahmanzadeh
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.